DE69213537D1 - HLE-inhibierende heterozyklische Amide - Google Patents

HLE-inhibierende heterozyklische Amide

Info

Publication number
DE69213537D1
DE69213537D1 DE69213537T DE69213537T DE69213537D1 DE 69213537 D1 DE69213537 D1 DE 69213537D1 DE 69213537 T DE69213537 T DE 69213537T DE 69213537 T DE69213537 T DE 69213537T DE 69213537 D1 DE69213537 D1 DE 69213537D1
Authority
DE
Germany
Prior art keywords
hle
heterocyclic amides
inhibiting
inhibiting heterocyclic
amides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69213537T
Other languages
English (en)
Other versions
DE69213537T2 (de
Inventor
Peter Robert Bernstein
Andrew Shaw
Royston Martin Thomas
Donald John Wolanin
Peter Warner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919108357A external-priority patent/GB9108357D0/en
Priority claimed from GB919108358A external-priority patent/GB9108358D0/en
Priority claimed from GB929205392A external-priority patent/GB9205392D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of DE69213537D1 publication Critical patent/DE69213537D1/de
Application granted granted Critical
Publication of DE69213537T2 publication Critical patent/DE69213537T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
DE69213537T 1991-04-18 1992-04-15 HLE-inhibierende heterozyklische Amide Expired - Fee Related DE69213537T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919108357A GB9108357D0 (en) 1991-04-18 1991-04-18 Heterocyclic amides
GB919108358A GB9108358D0 (en) 1991-04-18 1991-04-18 Heterocyclic compounds
GB929205392A GB9205392D0 (en) 1992-03-12 1992-03-12 Heterocyclic amides

Publications (2)

Publication Number Publication Date
DE69213537D1 true DE69213537D1 (de) 1996-10-17
DE69213537T2 DE69213537T2 (de) 1997-02-20

Family

ID=27265602

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69213537T Expired - Fee Related DE69213537T2 (de) 1991-04-18 1992-04-15 HLE-inhibierende heterozyklische Amide

Country Status (15)

Country Link
EP (1) EP0509769B1 (de)
JP (1) JPH0656785A (de)
KR (1) KR920019750A (de)
AU (1) AU660664B2 (de)
CA (1) CA2065794A1 (de)
CS (1) CS117692A3 (de)
DE (1) DE69213537T2 (de)
FI (1) FI921598A (de)
GB (1) GB9207145D0 (de)
HU (1) HUT66541A (de)
IE (1) IE921159A1 (de)
IL (1) IL101555A0 (de)
NO (1) NO921451L (de)
NZ (1) NZ242322A (de)
TW (1) TW262475B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521179A (en) * 1991-04-18 1996-05-28 Zeneca Limited Heterocyclic amides
US5486529A (en) * 1992-04-16 1996-01-23 Zeneca Limited Certain pyridyl ketones for treating diseases involving leukocyte elastase
EP0636143B1 (de) * 1992-04-16 1997-09-24 Zeneca Limited Peptide mit eine alphaaminoboronaire gruppe and ihre verwendung als elastasehemmer
CA2133658A1 (en) * 1992-04-16 1993-10-28 Peter R. Bernstein Heterocyclic derivatives
GB9307555D0 (en) * 1992-04-16 1993-06-02 Zeneca Ltd Heterocyclic compounds
US5441960A (en) * 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
GB9211783D0 (en) * 1992-06-04 1992-07-15 Ici Plc Amide derivatives
GB9214053D0 (en) * 1992-07-02 1992-08-12 Ici Plc Heterocyclic amides
US6608204B1 (en) * 1994-12-13 2003-08-19 Corvas International, Inc. Aromatic heterocyclic derivatives as enzyme inhibitors
US5656645A (en) * 1994-12-13 1997-08-12 Corvas International, Inc. Aromatic heterocyclic derivatives as enzyme inhibitors
US5658930A (en) * 1994-12-13 1997-08-19 Corvas International, Inc. Aromatic heterocyclic derivatives as enzyme inhibitors
DE69634122D1 (de) * 1995-04-27 2005-02-03 Mitsubishi Pharma Corp Heterocyclische amidverbindungen und deren medizinische verwendung
WO1997001338A1 (en) * 1995-06-27 1997-01-16 Merck & Co., Inc. Pyridinone-thrombin inhibitors
US5668289A (en) * 1996-06-24 1997-09-16 Merck & Co., Inc. Pyridinone thrombin inhibitors
US5872138A (en) * 1996-09-13 1999-02-16 Merck & Co., Inc. Thrombin inhibitors
US5869487A (en) * 1996-10-24 1999-02-09 Merck & Co., Inc. Pyrido 3,4-B!pyrazines for use as thrombin inhibitors
CN1088706C (zh) * 1996-10-25 2002-08-07 卫福有限公司 新型杂环酰胺化合物及其医药用途
US6017934A (en) * 1997-01-22 2000-01-25 Merck & Co., Inc. Thrombin inhibitors
US5792779A (en) * 1997-02-19 1998-08-11 Merck & Co., Inc. Pyridinone thrombin inhibitors
US6011038A (en) * 1997-09-05 2000-01-04 Merck & Co., Inc. Pyrazinone thrombin inhibitors
US6087373A (en) * 1997-09-23 2000-07-11 Merck & Co., Inc. Thrombin inhibitors
US6133297A (en) * 1997-09-30 2000-10-17 Merck & Co., Inc. Thrombin inhibitors
WO1999045928A1 (fr) 1998-03-11 1999-09-16 Welfide Corporation INHIBITEURS DE PRODUCTION D'ANTICORPS IgE ET INHIBITEURS DE MALADIES AUTO-IMMUNES
US6147078A (en) * 1998-05-19 2000-11-14 Merck & Co., Inc. Pyrazinone thrombin inhibitors
WO2000018762A1 (en) * 1998-09-28 2000-04-06 Merck & Co., Inc. Thrombin inhibitors
AU752186B2 (en) 1998-10-30 2002-09-12 Merck & Co., Inc. Thrombin inhibitors
US6610692B1 (en) 1998-10-30 2003-08-26 Merck & Co., Inc. Thrombin inhibitors
US6239132B1 (en) 1999-04-23 2001-05-29 Merck & Co., Inc. Thrombin inhibitors
UA58636C2 (uk) 1999-06-04 2003-08-15 Мерк Енд Ко., Інк. Піразинонові інгібітори тромбіну, фармацевтична композиція, спосіб інгібування утворення тромбів у крові, спосіб лікування станів, пов'язаних із тромбоутворенням
JP2003501389A (ja) 1999-06-04 2003-01-14 メルク エンド カムパニー インコーポレーテッド トロンビン阻害物質
EP1259506A1 (de) 1999-11-23 2002-11-27 Merck & Co., Inc. Pyrazinone thrombin inhibitoren
JP2003527426A (ja) 2000-03-23 2003-09-16 メルク エンド カムパニー インコーポレーテッド トロンビン阻害薬
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
PE20050159A1 (es) * 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
SE0302487D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
KR20070086610A (ko) 2004-11-24 2007-08-27 버텍스 파마슈티칼스 인코포레이티드 3-[2-(3-아실아미노-2-옥소-2ｈ-피리딘-1-일)-아세틸아미노]-4-옥소-펜탄산 유도체 및 카스파제 억제제로서의 이의용도
CA2610400A1 (en) 2005-06-07 2006-12-14 Pharmacopeia, Inc. Azinone and diazinone v3 inhibitors for depression and stress disorders
MX2007015419A (es) * 2005-06-08 2008-02-21 Novartis Ag Compuestos organicos.
CN110950807B (zh) * 2018-09-26 2023-03-03 中国科学院上海药物研究所 联芳基类化合物、其制备方法、药物组合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474778A (en) * 1983-11-09 1984-10-02 E. R. Squibb & Sons, Inc. Lactam containing compounds, their pharmaceutical compositions and method of use
GB8600263D0 (en) * 1985-01-22 1986-02-12 Ici America Inc Peptide derivatives

Also Published As

Publication number Publication date
IE921159A1 (en) 1992-10-21
HUT66541A (en) 1994-12-28
IL101555A0 (en) 1992-12-30
FI921598A (fi) 1992-10-19
EP0509769A2 (de) 1992-10-21
NZ242322A (en) 1994-12-22
KR920019750A (ko) 1992-11-19
EP0509769A3 (en) 1993-09-01
GB9207145D0 (en) 1992-05-13
FI921598A0 (fi) 1992-04-10
AU660664B2 (en) 1995-07-06
CA2065794A1 (en) 1992-10-19
AU1482792A (en) 1992-10-22
HU9201225D0 (en) 1992-07-28
EP0509769B1 (de) 1996-09-11
TW262475B (en) 1995-11-11
NO921451D0 (no) 1992-04-10
JPH0656785A (ja) 1994-03-01
DE69213537T2 (de) 1997-02-20
CS117692A3 (en) 1992-11-18
NO921451L (no) 1992-10-19

Similar Documents

Publication Publication Date Title
DE69213537D1 (de) HLE-inhibierende heterozyklische Amide
NO930193D0 (no) Biarylsubstituerte 4-aminosmoersyreamider
NO20010837D0 (no) Heterocykliske iminer
DK371989D0 (da) Amidderivater
DE69429147D1 (de) Benzamidderivate
DE3685829D1 (de) Heterocyclische amide.
NO920157L (no) Heterocykliske hydroksylaminer
NO930760D0 (no) Substituerte fenyleddiksyreamider
NO962078D0 (no) Alfa-aryl - eller heteroaryl-substituerte amid-ester ACAT-inhibitorer
NO954323D0 (no) Heterocykliske derivater
NO970684D0 (no) Nye N-substituerte naftokondenserte laktamer
FI950486A (fi) Amidijohdannaiset
ZA916902B (en) Hetrazepinoid amide derivatives
NO930722D0 (no) Imidazolylsubstituerte fenyleddiksyreamider
LV10448A (lv) Piperazinilkamparsulfoniloksitocina antagonista aizvietotie amidu atvasinajumi
BR9408029A (pt) Derivados de 3-azabicicloalcanos N-substituídos
NO933170D0 (no) Heterocykliske forbindelser
NO924465D0 (no) Kinolylmetoksyfenyl-eddiksyreamider
FI955818A0 (fi) Uudet heterosykliset amidit
DE69117404D1 (de) Polyphenylenäther-Polyätheramidmischungen
DE59308465D1 (de) Segmentierte N-Alkyl-Polyurethanamide
IS3664A7 (is) Ný amíð
GB9108357D0 (en) Heterocyclic amides
SE9002439D0 (sv) New amides ii
NO920020D0 (no) N-(merkaptoalkyl)amider

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASTRAZENECA UK LTD., LONDON, GB

8339 Ceased/non-payment of the annual fee